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Abstract
The synapses transmit signals between neurons in an ever-changing fashion.
Changes of synaptic transmission arise from numerous mechanisms known as syn-
aptic plasticity. The importance and complexity of the synapse has fueled research
into the molecular mechanisms underlying synaptogenesis, synaptic transmission,
and plasticity. Particularly, homeostatic plasticity refers to the local changes in
synaptic activation to generate local synaptic adaptations and network-wide
changes in activity to generate adjustments between excitation and inhibition. This
review chapter will focus on synaptic phenomena and mechanisms that are likely to
contribute to network homeostasis. In addition, it will be discussed a putative
modulation of the signaling mechanisms serving a homeostatic function as a viable
therapeutic approach for disease modification in neurological and neurodegenera-
tive disorders. To sum up, the main role of the following players in homeostatic
plasticity will be analyzed, based on what a growing body of evidence has suggested
recently: BDNF-mediated TrkB system activation; adenosine modulation system;
nitric oxide/soluble GC/cGMP signaling; astrocyte involvement—astroglial CB1
receptors; the microtubule-associated neuronal protein Tau; the signaling pathway
of the Wnt protein family; extracellular vesicles in the intercellular communication;
and estrogen involvement in non-reproductive functions.
Keywords: adenosine, astrocytes, BDNF, estrogens, extracellular vesicles,
neurodegeneration, nitric oxide, synaptic plasticity, Tau, TrkB system,
Wnt proteins
1. Introduction
The neurotransmission may be defined as the set of biochemical and
physiochemical signals which establishes neuronal communication. Changes of
synaptic transmission arise from numerous mechanisms known as synaptic plastic-
ity. Synaptic plasticity is crucial for regulating synaptic transmission or electrical
signal transduction to neuronal networks, for sharing essential information among
neurons and for maintaining homeostasis in the body.
Synaptic plasticity in the mature nervous system includes structural and
morphological modifications constituting the cellular response to the changes in
neuronal activity that are thought to be responsible for learning and memory [1].
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The individual synaptic connections are constantly removed or recreated depending
on the neuronal environment. This plasticity is highly regulated by signals from
other cells of the nervous system, mainly the astrocytes whose function is the
maintenance of the neurons in a determined position [2]. This modeling ability is
achieved by genetic, molecular, and cellular mechanisms that influence synaptic
connections and neuronal circuits.
Various neurotransmitter receptors are functionally associated with protein
kinases and other G-proteins that modulate cascades of molecules which in turn
maintain essential cellular functions [3]. Modifications of the MAPK- and cAMP-
related signaling pathways may affect intracellular Ca2+ levels, neurotransmitter
receptors, transcription factors, and the cross-link between signaling pathways,
among other biological functions which are essential for neuroplasticity [4].
At the structural level, synaptic plasticity entails incorporation or disassociation
of α-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA) receptors
from the postsynaptic membrane and the growth or constriction of the dendritic
spines where most excitatory synapses are placed [5]. At the functional level,
synaptic plasticity is considered as the long-term potentiation (LTP) or long-term
depression (LTD) of synaptic strength, with modifications in conductance through
AMPA receptors in the postsynaptic membrane. During the term of plasticity,
N-methyl-D-aspartate (NMDA) receptor activation leads to Ca2+ ions passage
through the postsynaptic membrane to trigger intracellular signaling cascades.
These events set off gene transcription, trafficking of AMPA receptor via action
dynamics, cytoskeleton reorganization, and enlargement or removal of dendritic
spines. The integrity of the synaptic structure, trafficking of AMPA receptor, and
dendritic spine dynamics are all crucial for generating lasting synaptic plasticity
modifications [5].
The AMPA receptors and NMDA receptors are the ones which synergize at
postsynaptic terminals to facilitate different forms of synaptic plasticity. Constant
activation of AMPA receptors by a series of impulses arriving at presynaptic termi-
nals leads to depolarization of the presynaptic membrane, which removes the Mg2+
ions that are obstructed at NMDA receptors [6]. Thereon, the simultaneous
excitation of pre- and postsynaptic neurons speeds up the gating of NMDA channels
and reinforces the synapse. This feature is crucial in NMDA channels for being
specifically associated with synaptic plasticity and its high permeability to Ca2+ ions.
Therefore, the second messenger Ca2+ modulates a set of signaling pathways and
the responses that collectively lead to synaptic modification [6].
Furthermore, local changes in synaptic activation to generate local synaptic
adaptations and network-wide changes in activity result in adjustments between
excitation and inhibition. These mechanisms are likely to contribute to network
homeostasis. Therefore, this review chapter will focus on synaptic phenomena
involved in homeostatic plasticity. In addition, it will be discussed a putative mod-
ulation of the signaling mechanisms serving a homeostatic function as a viable
therapeutic approach for disease modification in neurological and neurodegenera-
tive disorders.
2. BDNF-mediated TrkB system activation
Synaptic plasticity at the molecular level can be driven by increased expression
of plasticity-related genes, such as brain-derived neurotrophic factor (BDNF), cal-
cium/calmodulin kinase II (CaMKII), and cAMP response element binding (CREB)
protein, as well as by an augmented expression of both AMPA and NMDA receptors
on surface [7].
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Biogenic Amines in Neurotransmission and Human Disease
The escalation of the synapse is a mode of homeostatic plasticity in which a
prolonged enhancement in neuronal activity leads to a compensatory decline in
excitatory transmission that is often mediated by a drop in levels of the synaptic
AMPA receptors. The blockage of sustained activity results in the opposite effect,
that is, an enhancement in excitatory transmission that is often mediated by an
augmentation in levels of the synaptic AMPA receptors [8]. The neurotrophin
BDNF and its signaling partners are the main regulators of synaptic plasticity.
BDNF may serve as a real mediator rather than simply a modulator of synaptic
plasticity and synaptic communication. As BDNF is synthesized and released in an
activity-dependent manner [9], BDNF levels could serve as signals for changes in
neuronal activity and thereby mediate synaptic scaling. BDNF and neurotransmitter
signaling cascades can work together in close temporal association to induce imme-
diate and guided effects on synaptic plasticity. What is more, specifically interfering
with BDNF-related signaling is a crucial strategy for neuronal and functionally
restorative treatments for neurological and psychiatric disorders [10].
The main functions of BDNF are mediated by its interaction with the
tropomyosin-related kinase B (TrkB) receptor [11] whose intracellular signaling
cascade activation can affect synaptic transmission and synaptic contact formation
[12]. TrkB receptors are typically localized within vesicles inside the cell and trans-
locate to the plasma membrane through neuronal activity [13]. The early effects of
BDNF are a result of the modification (e.g., protein phosphorylation) of compo-
nents that are already present at the synapse, while the long-term effects originate
from the modification of translational activity at the synapse and changes in tran-
scription. Stimulation of high-frequency inducing LTP leads to enhancement of
BDNF production [14]. Furthermore, BDNF increases neurotransmitter release and
promotes synaptic transmission and LTP [15]. Thus, it is assumable that the effects
exerted by BDNF on synaptic plasticity are TrkB mediated.
A recent study has investigated the features of neural network formation and
functions in primary hippocampal cultures in the context of chronic BDNF appli-
cation and TrkB receptor blockage [16]. It has been demonstrated that the blockage
of TrkB receptors affected the structures of synapses and even mitochondria, which
were not regarded as capable of participating in synaptic modulation for a long
period. Nevertheless, it has been shown that TrkB-mediated signaling can affect
both the ultrastructural and functional parameters of brain mitochondria, even in
normal oxygen and nutrient supply conditions. Chronic TrkB receptor blockade
leads to destructive ultrastructural changes in mitochondria, whereas the functional
activity of organelles remains intact apparently. Long-term application of BDNF
enhances the enzymatic activity of mitochondria, though this modification is not
related to changes in ultrastructure of organelles. These findings might demonstrate
that TrkB-mediated mitochondrial regulation is associated with functional changes
of the enzymatic apparatus of the respiratory chain but not with structural
reshaping of organelles. Chronic BDNF application increased the basal oxygen
consumption rate via activating respiratory chain complex II [17]. Under oxygen
stress conditions, BDNF increases the adaptive potential by impacting the func-
tional parameters of the mitochondrial apparatus. Further research should address
whether the TrkB-mediated pathway for influencing mitochondria is generalized
(i.e., carried out through nuclear genes) or directed toward an isolated organelle.
A genetically determined high level of BDNF can provide significant adaptive
potential to the nervous system, and its neuroprotective effects are induced via the
TrkB receptor system [18]. To date, it has been found that BDNF-mediated TrkB
system activation accounts for the formation of more complex functionally active
neural networks with a great level of efficiency in synaptic transmission. Thus, the
TrkB signaling system can be involved in higher cognitive functions.
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Recent progress into the etiology of neurological and metabolic diseases has been
made with genome-wide association studies. BDNF/TrkB signaling contribution to
synaptic development and plasticity, neurite outgrowth, and dendritic spine for-
mation is a possible anatomical correlate of hyperconnectivity in autism-spectrum
disorder (ASD) [19] or of hypoconnectivity in monogenic obesity [20].
Growing evidence suggests that BDNF upregulation plays a key role in the
increased trophic effects in ASD. Studies on functional image have shown that, in
most young ASD patients, cortical regions appear hyperlinked, and cortical thick-
ness and brain size are enhanced [19]. These findings indicate that developing ASD
brains may occur in a modified neurotrophic environment as some ASD patients
and animal models have shown enhanced levels of BDNF.
Besides that, genome association studies now reveal different candidate obesity
genes, most of which are strongly expressed or known to act in the CNS, highlight-
ing the role of the brain in propensity to obesity. In this regard, BDNF is involved in
energy metabolism and eating behavior as partial BDNF deficiencies in mouse
models cause hyperphagia and obesity. The first case described by disruption of the
BDNF gene (11p13) in humans was that of an 8-year-old obese girl, who presented
an abnormality in chromosome 11 that altered the BDNF gene in one of the chro-
mosomal breakpoints [21]. This patient with severe hyperphagia and obesity also
presented a complex neurobehavioral phenotype, including impaired cognitive
function and memory and a distinctive hyperactive behavior.
3. Adenosine modulation system
Adenosine is a ubiquitous molecule that is directly involved in the key processes
sustaining cellular viability and adaptability, this is it, the energy charge, redox
control, DNA and RNA, and epigenetic control. The role of adenosine in the brain is
of great interest since the adenosine receptors are far more abundant in the brain
than in any other organ or cell type in mammals [22]. Though there are four plasma
membrane metabotropic receptors such as adenosine A1, A2A, A2B, and A3 recep-
tors [23], A1 and A2A receptors are the responsible ones for the effects of adenosine
in the brain. A1 receptors (A1R) are the most abundant and widely distributed,
while A2A receptors (A2AR) are more abundant in the basal ganglia and in synapses
throughout the rest of the brain. Both A1R and A2AR are mostly located in synap-
ses, particularly in glutamatergic synapses, although both receptors are also present
in other synapses [24].
Adenosine acts on A1R at a pre-synaptical level decreasing calcium influx and
glutamate release, at a post-synaptical level decreasing the activation of ionotropic
glutamate receptors and of voltage-sensitive calcium channels as well as
hyperpolarizing dendrites through a control of potassium channels. The ability of
A1R to control high-frequency-induced synaptic plasticity contrasts with that of
A2AR. Thus, A2AR are capable of enhancing the evoked release of glutamate in
different brain areas and the function of ionotropic glutamate receptors [25].
Besides, A2AR behave as fine-tuners of other neuromodulation systems, since
A2AR activation is a requirement for the synaptic effects of growth factors or
neuropeptides. What is more, A2AR activation diminishes the efficiency of pre-
synaptic inhibitory systems. Thus, A2AR commute pre-synaptic modulation from
inhibitory to facilitatory. Another significant feature of A2AR is that they have also
been found in astrocytes and microglia cells, controlling Na+/K+-ATPase, the uptake
of glutamate, the production of pro-inflammatory cytokines, and the effects
potentially contributing to the selective A2AR-mediated control of synaptic
plasticity [26].
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Different sources of extracellular adenosine activate each of these adenosine
receptors in order to control synaptic transmission by A1R and synaptic plasticity
by A2AR [27]. The predominant role of adenosine under basal conditions, in excit-
atory synapses, is an A1R-mediated inhibition of synaptic transmission. Then, an
endogenous A1R-mediated inhibitory tonus takes place under most experimental
conditions. In contrast, A2AR are only recruited upon higher frequencies of nerve
stimulation triggering plastic changes of synaptic efficiency (LTP) [28]. This selec-
tivity is consequence of the adenosine formed by synaptic ecto-nucleotidases upon
release of ATP from nerve terminals; high-frequency stimulations are needed to
trigger an excessive release of ATP [29] that significantly results in the production
of extracellular adenosine near A2AR. These A2AR then enhance the release of
glutamate and the activation of NMDA receptors, effectively reinforcing the
implementation of LTP [30].
Furthermore, the particular activation of A2AR upon higher frequencies of nerve
stimulation favors the solution of the increased feedback inhibitory synaptic mecha-
nisms with increasing frequencies of synaptic recruitment. The higher the stimula-
tion frequency, the greater the extracellular levels of adenosine and of cannabinoids
since supramaximal activation of pre-synaptic A1R or of cannabinoid CB1R can block
synaptic transmission. The neuromodulator adenosine, by operating high affinity
adenosine receptors, restrains transmission via A1 receptor (A1R) or CB1R [31].
In spite of the selective involvement of A2AR that allows simultaneously miti-
gating pre-synaptic inhibition and strengthening synaptic facilitation at the single
synapse level, A1R and A2AR actually collaborate to encode the relevance of infor-
mation at the level of brain circuits. The implementation of a potentiated transmis-
sion in a given synapse will elicit in parallel a process of hetero-synaptic depression
involving synaptic strengthening of A1R function in surrounding synapses (with
respect to this potentiated synapse). The increased recruitment of a synapse set off
the activation of the astrocytic syncytium. Within the domain covered by this
syncytium, there will be a greater astrocytic (i.e. non-synaptic) release of ATP [32],
which will be degraded by ecto-nucleotidases degrading ATP into adenosine, which
is channeled into A1R, further depressing the activity of neighboring synapses
(where A2AR are not engaged).
In conclusion, a predominant role of neuronal A2AR in the control of neuronal
damage is supported by several studies [33]. Dysfunction and damage of synapses
may be triggered by the A2AR that are located synaptically. This synapse impair-
ment is regarded as one of the earliest alterations found in different neurodegener-
ative disorders ranging from Alzheimer’s disease (AD) to depression.
Experimentally, it has been shown that blockade of A2AR prevents memory dam-
age in AD models. Therefore, the question arises whether A2AR antagonists might
have a therapeutic potential. To give some answer, a triple transgenic AD model
(3-Tg-AD) has been used with a defined onset of memory dysfunction occurring
at the age of 4 months. After the onset of memory deficits in 3-Tg-AD mice, a
treatment of 3 weeks with a selective A2AR antagonist has shown to normalize the
up-regulation of hippocampal A2AR, restore hippocampal-dependent reference
memory, and decrease hippocampal synaptic plasticity and global and
glutamatergic synaptic markers as well. These findings may point to a therapeutic-
like ability of A2AR antagonists to recover synaptic and memory dysfunction that
occur in early AD [34]. It may be assumed a role for A2AR in the early steps of
neurodegeneration, whereby the up-regulation of A2AR that occurs at the begin-
ning in synapses upon noxious brain insults [27] would set off an aberrant
overenforcement of synaptic plasticity that would interrupt synaptic function and
favor the likelihood of excitotoxic destruction of the synapse. A2AR would facilitate
synaptic plasticity under physiological conditions, while their up-regulation would
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lead to a synaptic toxicity that occurs early during the course of neuropsychiatric
illnesses. Moreover, the up-regulation and role of A2AR in the astrocyte and
microglial control suggest an involvement of A2AR in brain damage, which might
also include the control of blood flow and endothelial permeability by these recep-
tors. This entails that multiple cellular sites of action of A2AR would participate in
the ongoing process engaged in neurodegeneration [33].
4. Nitric oxide/soluble GC/cGMP signaling in synaptic plasticity
Nitric oxide (NO) plays roles in maintaining synaptic plasticity and in helping to
restore plasticity in the neuronal architecture in the CNS. NO is regarded as a
chemical transmitter which has essential functions in the mammalian central as well
as peripheral nervous system [35]. NO is the second mediator that can activate
NMDA receptors. NMDA receptor activation persistently enhances the activity of
neuronal nitric oxide synthase (nNOS) in the neuronal cytoplasm. It then catalyzes
the generation of endogenous NO from L-arginine followed by the enhanced release
of NO from neurons. Activation of these receptors by glutamate stimulates the
calcium influx into cells and the generation of NO by NOS, which rapidly stimulates
guanylate cyclase and increases cGMP synthesis [36]. Other glutamate receptors,
such as AMPA, can also produce NO; this pathway modulates the release of gluta-
mate and dopamine. Nevertheless, AMPA receptor trafficking, expression, and
S-nitrosylation activity are maintained by NO. Specifically, the N-ethylmaleimide-
sensitive factor (NSF, an ATPase) is high in neurons which binds with GluR2 and
the NSF-GluR2 interaction has shown to be important to maintain AMPA-mediated
transmission at the synapse [37]. Physiologically, synaptic NSF is S-nitrosylated by
NO from neuronal source in the mouse brain. Activation of NMDA receptors
increases the NSF-GluR2 interaction, as well as the surface insertion of GluR2.
NMDA receptors stimulate NO generation, which enhances NSF S-nitrosylation,
stimulates its association with GluR2, and increases the surface expression of
GluR2-containing AMPA receptors [38].
Additionally, NO is associated with the storage, uptake, and release of mediators,
such as acetylcholine, noradrenaline, GABA, taurine, and a glycine. NO can stimulate
its own extrasynaptic receptors, which are located some distance from sites of NO
synthesis. In addition, nNOS-containing neurons actively participate in the rostral
path of neuroblast migration, which involves new synaptic connections and influ-
ences neurogenesis [39]. Astrocyte migration is also regulated by the release of NO
under the actions of inducible nitric oxide synthase (iNOS). NO is also recognized as
critical for the formation of synapses and the growth of nerve fibers [40].
Deficits in synaptic plasticity are increasingly recognized as causes of memory
loss in AD [41]. NO is produced by NOS through NMDAR-mediated calcium input.
NO signaling comes into play in neurodegenerative diseases via the generation of
reactive nitrogen species and cGMP signaling cascades. NO also exerts
neuroprotective effects, as shown in AD mouse models, by reducing cell loss and
Tau pathology [42]. In AD models, NO has shown to be altered through various
mechanisms. For example, the NMDAR-mediated calcium entry that activates NOS
is enhanced by abnormal ryanodine receptor-(RyR-) mediated calcium-induced
calcium release. NOS and RyR protein levels are also increased in both AD mouse
models and human AD brains. In ADmice, at the presynaptic level, these conditions
increasing NO levels take place alongside excessive hippocampal synaptic depres-
sion. These deficits occur when homeostasis is placed at risk, such as in the presence
of reduced RyR-calcium release. Consequently, the hippocampal network and
cognitive function are not normal, though they appear to be so [43].
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In a study on 3-Tg-AD mice, the presynaptic terminals have shown to be the
primary site of NO regulation, with increased evoked and spontaneous vesicle
release, as determined by paired-pulse facilitation assays and spontaneous vesicle-
release properties [44]. Moreover, NO modifies the magnitude of vesicular release
by transforming spare vesicles into easily releasable vesicles [45]. In addition, NO
can increase the opening of RyR channels, possibly by means of S-nitrosylation. The
opposite interactions between augmented RyR-calcium signaling and enhanced
nNOS expression in AD neurons can sustain an increased NO production or syn-
thesis and also strengthen the presynaptic gain. At the postsynaptic level, the
neuroprotective characteristics of NO become evident by inhibiting the excessive
NMDAR-induced calcium influx and excitotoxicity via S-nitrosylation of the NR2A
subunit of the NMDA receptor. At the same time, apoptosis is decreased through
the S-nitrosylation of caspase-3, -8, and -9. The enhanced nNOS activity and NO
levels in AD brains might be neuroprotective, as proven by the selectively preserved
NOS-positive neurons in AD. Hence, continuous increases in NO exert harmful
effects, such as oxidative stress, the shredder loss of synaptic function, and
apoptosis [46].
All in all, the NO up-regulation or down-regulation may result in neuropsychi-
atric conditions, and its improvement may restore synaptic plasticity and neuronal
function. Understanding the specific molecular mechanisms maintaining these
effects can give some light as to identify ways to treat these neuropsychiatric
conditions [47]. Particularly, pathological deficits in NO signaling have been
reported in corticostriatal circuits in Huntington’s disease (HD). Studies indicate
that deficits in cortical and striatal nNOS activity and nitrergic transmission may
contribute to the progression of corticostriatal pathway dysfunction observed in
HD. In this pathology, medium-sized spiny neurons (MSNs) projecting to the
external globus pallidus appear to preferentially degenerate as a consequence of
accumulation of the abnormal huntingtin protein. What is interesting is that cortical
stimulation increases striatal NOS activity by means of a NMDA and dopamine D1
receptor-dependent mechanism. Thus, studies on nNOS knockout mice have
proven that striatal MSNs are significantly less sensitive to cortical drive when
compared with wild-type controls, indicating that NO signaling plays a critical role
in maintaining corticostriatal transmission [48]. Therefore, deficiencies in nNOS
activity and NO signaling reported in HD could be associated with decreased excit-
atory corticostriatal transmission and motor dysfunction. From this concluding
remark, it is likely that HD patients might benefit from pharmacotherapies aimed to
favor nitrergic signaling and corticostriatal transmission.
Conversely, the protective effect of NMDA antagonists in conditions of in vivo
cerebral ischemia supports that influx of Ca2+ through NMDA-receptor channels
constitute the main driver of glutamate neurotoxicity, a mechanism being of path-
ological importance. Studies on the role of NO in NMDA-mediated
neurodegeneration have given some light with the use of mice lacking individual
NOSs subjected to ischemia. For instance, it has been found that nNOS contributed
to the early damage, whereas endothelial NOS (eNOS) was protective, reflecting its
relevance in cerebral blood flow and, likely, in inhibiting both leucocyte adhesion to
the endothelium and platelet aggregation [49]. Reduced synthesis and availability of
eNO may contribute to the development of dementia by favoring the onset and
progression of atherosclerosis, vasoconstriction, and impaired cerebral blood flow
regulation. Furthermore, the inducible isoform of NOS (iNOS) that starts to be
expressed in the following days to an ischemic event appeared to provide additional
damage. iNOS is expressed in macrophages and glial cells in response to pro-
inflammatory cytokines or endotoxin. In the brain, widespread expression of iNOS
is pathologic and has been observed in neurological diseases, such as multiple
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sclerosis, stroke, and AD. Increased NO production and iNOS expression have been
observed after experimental and clinical traumatic brain injury (TBI). iNOS knock-
out mice showed reduction in infarct volume and motor deficits after focal ischemia
compared with wild-type mice. In an exploratory phase II study trial, TBI patients
treated with the most selective inhibitor of human iNOS reported to date showed
significant improvement in clinical outcome [50]. These studies suggested a
neuroprotective effect of iNOS inhibition after TBI.
5. Astrocyte involvement—astroglial CB1 receptors
Astrocytes are the most abundant glial cell population in the brain [51]. One of
the most intriguing features of astrocytes is the control of synaptic plasticity and
memory functions. Astrocytes contribute in shaping different types of synaptic
plasticity that challenges the generation of experimental models enabling the dis-
tinction between the neuronal contribution and the astroglial contribution in the
control of a given function [52].
The finding of a large number of astrocytes and increased expression of the α7
nAChRs subunit on these cells in hippocampus and temporal cortex of sporadic AD
patients have suggested an involvement of the astrocytic α7 nAChRs in the metab-
olism of Aβ and a relationship with the amyloid cascade [53]. It has been proven
that Aβ, at physiological levels, controls synaptic activity and acts as a positive or
negative regulator post-synaptically. In fact, Aβ either activates or inhibits α7
nAChRs in a dose-dependent manner. In the healthy brain, Aβ enhances spontane-
ous astrocyte calcium transients, regulating neuron-glia signaling in a nAChR-
dependent manner [54]. On the other hand, Aβ accumulation increases astrocytic
α7 nAChRs expression and subsequently increases intracellular calcium released
from intracellular stores contributing to a number of inflammatory cascades.
The nAChRs from astrocytes can be activated by the transmitters released from
presynaptic terminals or neurotransmitters located in the interstitial space [52]. For
instance, the nAChRs agonist acetylcholine elevates intracellular calcium in astro-
cytes, stimulating the release of glutamate gliotransmitter and consequently the
NMDA receptor-dependent currents in neurons. It results in an increase of the
efficient synaptic transmission and strength. This mechanism explains the Aβ-
induced hippocampal LTP. Then, Aβ-α7 nAChRs interaction increases astrocytic
activity to induce glutamate gliotransmission which contributes to synaptic plastic-
ity and cognition [55]. However, pathological concentrations of Aβ, as occurred in
AD, induces LTD as Aβ oligomers-induced glutamate release from astrocytes causes
excitotoxic damage and synaptic loss in neurons. In essence, pathological levels of
Aβ cause α7 nAChR-induced gliotransmission dysregulation leading to increased
excitability within the hippocampal neural network [56]. What is more, endoge-
nous stimulation of α7 nAChRs on astrocytes causes expression of further AMPA
receptors post-synaptically at glutamatergic synapses of neurons. Consequently, the
ratio of AMPA-evoked synaptic currents increases.
There is evidence that GABA is abundantly produced and released by activated
astrocytes. A non-physiological increase in tonic GABA release from reactive astro-
cytes in the hippocampus may be directly responsible for the memory impairment
in AD. It has been shown that alterations of kynurenic acid, an astrocyte-derived
antagonist of the α7 nAChRs, are associated with the impairment of the cognitive
function in AD patients. In fact, kynurenic acid at low concentrations inhibits
GABAergic neurotransmission triggered by α7 nAChRs activation [57]. Therefore,
prevention of GABAergic neurotransmission by α7 nAChRs inhibition through
kynurenic acid may protect against AD.
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The α7-specific agonists decrease IL-6 production in cell lines derived from astro-
cytes. Conversely, internalization of these receptors in astrocytes by binding to α7-
specific antibodies could stimulate IL-6 production. The α7 nAChRs internalization
might provoke neuroinflammation within the brain by inducing IL-6 production in
astrocytes. Furthermore, evidence shows that treatment with different α7 nAChRs
agonists prevent neuroinflammation in AD-affected brains and suppress elevated
levels of astrocyte-related pro-inflammatory cytokines, such as TNF-α [58].
Microglia play different roles in the healthy brain which include neuronal syn-
apse monitoring, phagocytosis of neuronal debris, and cell migration as well as
proliferation. Microglia show a typical resting phenotype in the healthy CNS,
becoming activated in response to excessive neuronal activity during neurochemical
or electrically stimulations. It has been shown that increased activation of astrocytic
α4β2 and α7 nAChRs drives the expression of glial cell-derived neurotrophic factor
(GDNF) [59]. Astrocyte-derived GDNF binds to GDNF family receptor alpha1
(GFRα1) and activates intracellular signaling pathways that lead to inhibition of
microglial activation and protection of neurons from neurodegeneration [60].
The astroglial type-1-cannabinoid (CB1) receptor signaling recently emerged as
the mediator of several forms of synaptic plasticity associated to important cogni-
tive functions [61]. The presence of CB1 and type-2 (CB2) receptors in astrocytes
was first described in human and rodent primary cultures. Particularly, CB1 recep-
tors are mainly located at presynaptic terminals of different types of neurons,
inhibiting neurotransmitter release. Although the signaling of CB1 receptors in
astrocytes has been partially investigated, it has been suggested that they are able to
couple to different intracellular signaling pathways in this type of cells, therefore
providing high adaptability to endocannabinoid-mediated responses in these cells.
The first endocannabinoid identified was arachidonoyl-ethanolamide, known as
anandamide [62]. Arachidonoyl-ethanolamide mimics the cannabinoid “tetrad”
effects (i.e., hypolocomotion, antinociception, catalepsy, and hypothermia) in
rodents. The second discovered endocannabinoid, 2-arachidonoyl-glycerol (2-AG)
is considered as the main effector of most of the CB1 receptor-mediated endoge-
nous regulation of synaptic transmission. Endocannabinoids’ precursors are located
in cell membranes and their transformation into actual endocannabinoids is thought
to mainly occur in an activity-dependent manner. Endocannabinoids are likely
produced, mobilized, and degraded by astrocytes in vivo, suggesting the presence of
an astroglial autocrine and/or paracrine endocannabinoid signaling.
Astrocytic processes express transporters GLT-1 and GLAST for glutamate, par-
ticipating in the rapid removal of glutamate released into the synaptic cleft, which is
essential for both the termination of synaptic transmission and maintenance of
physiological neuronal excitability. Since increased stimulation of glutamate recep-
tors is highly toxic for neurons, glutamate uptake by astrocytes is crucial for
protecting neurons against excitotoxicity. In this regard, it has been observed that
pharmacological blockade of CB1 receptors reduces epileptiform discharges of hip-
pocampal slices through a direct control on astrocytic calcium signaling, suggesting
that over-activation of astroglial CB1 receptors might promote the maintenance of
brain excitotoxicity [61].
Intriguingly, whereas CB1 receptors on glutamatergic neurons have been found to
reduce glutamate release and excitoxicity, astroglial CB1 receptors have been shown
to promote astroglial-dependent activation of glutamatergic transmission [63]. These
potentially opposite effects at neurons or astroglial cells might indicate the complex-
ity in the regulation of excitatory output by the endocannabinoid system.
However, arachidonoyl-ethanolamide has shown to reverse AMPA-induced
neurotoxicity and down-regulation of GLT-1 and GLAST (glutamate transporters)
mRNA in cultures of mouse astrocyte and in the spinal cord of a mouse model of
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multiple sclerosis via CB1 receptor [64]. Thus, the role of astroglial CB1 receptors in
the regulation of excitatory amino acids in the context of excitotoxic processes
might depend on the conditions of the brain circuits involved and the specific
activation of the endocannabinoid system at different sites. It might be hypothe-
sized that astroglial CB1 receptors might exert a bidirectional control of excitatory
transmission and excitotoxicity [61].
The role of astroglial CB1 receptors in the modulation of excitatory transmission
in the hippocampus was first reported by Navarrete and Araque [65]. They found
that hippocampal astrocytes express functional CB1 receptors that increase intra-
cellular Ca2+ levels in astrocytes following electrical stimulation of adjacent neurons.
CB1 receptor-dependent increase of intracellular Ca2+ levels in astrocytes requires
activation of PLC, suggesting that the interaction of CB1 receptors with the Gαq
protein subunit may be favored in astrocytes as compared to neurons. Astroglial
CB1 receptors activation is necessary for NMDA receptor-mediated neuronal excit-
ability evoked by astrocyte Ca2+ elevations, suggesting their importance for
astrocyte-neuron excitatory signaling. However, these results do not characterize
neither the endogenous NMDA receptor agonist implicated in this process nor the
cellular origin and identity of the released eCBs that act at astroglial CB1 receptors
in these conditions. Astroglial CB1 receptors mediate heterosynaptic potentiation at
excitatory CA3-CA1 synapses in a Group I mGluR-dependent fashion. Importantly,
this phenomenon coexists with depolarization-induced suppression of excitation
(DSE, short-term inhibition of excitatory transmission) mediated by neuronal CB1
receptors at homosynaptic connections [66].
Finally, astroglial CB1 receptors mediate spike timing-dependent LTD (tLTD) in
the neocortex. tLTD is induced by paired stimulations of the pre- and postsynaptic
elements, leading to a reduction of presynaptic release of glutamate. CB1 receptor-
dependent tLTD has been also described at cortico-striatal synapses and may imply
astroglial CB1 signaling as well. This form of synaptic plasticity has been associated
to the neuronal coding of sensory experiences in vivo. Interestingly, one of the major
consequences of exogenous cannabinoids administration, including THC, is an
alteration of perception, but little is known about the mechanisms underlying these
effects [67]. Therefore, it is possible that the overstimulation of CB1 receptors
impairs sensory functions by a deregulation of tLTD.
6. The microtubule-associated neuronal protein Tau
The neuronal cytoskeleton is the major intracellular structure that determines
the morphology of neurons and plays a critical role in the development of the
nervous system, neuronal plasticity, and neurodegenerative diseases [68]. In par-
ticular, changes in microtubule (MT) dynamics are involved not only in axon
formation and axonal sprouting but also in mediating structural and functional
changes of dendritic spines, which represent the major site of excitatory postsyn-
aptic input [69].
MT dynamics are regulated by several factors affecting the assembly state of this
polymer. MT-associated proteins (MAPs) promote MT nucleation and elongation in
a compartment-specific manner and are also subject to regulation by posttransla-
tional modification [69]. Tau is of particular importance since it becomes enriched
in the axonal compartment during neuronal development and redistributes to the
somato-dendritic compartment in a state of hyperphosphorylation during neurode-
generative pathologies such as AD and other tauopathies [70]. Strikingly, acute or
chronic knockdown of Tau does not appear to affect MT stability and organization
or the overall structure of a neuron to a major extent. This feature raises the
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question whether Tau possesses activities beyond its direct role in regulating axonal
MT polymerization, which is altered in AD and other tauopathies. In this regard,
Tau is an intrinsically disordered protein, which interacts with different partners.
Tau stands out for its structural plasticity allowing it to react quickly in response to
changes in their environment by posttranslational modifications [71]. Then, Tau
may affect various signaling and regulatory processes dependent on its modifica-
tion, thereby regulating the function and plasticity of neurons during learning,
memory, and degenerative processes.
In order to make a functional assessment of Tau role with regard to neuronal
activity and network properties, several electrophysiological studies have been
performed using Tau knock-out (KO) mice or Tau knockdown experiments. Com-
plete absence of Tau or a decrease in the amount of Tau on neuronal activity has
been studied by recordings from individual cortical neurons as well as from intact
neuronal circuits in acutely isolated tissue slices. The focus in most studies was
placed on the influence of Tau on LTP or LTD generation in the hippocampus both
being established experimental paradigms of synaptic plasticity underlying learning
and memory formation. Cantero et al. [72] has studied the involvement of Tau in
shaping electrophysiological properties of neural oscillations in different neocortical
regions and hippocampus during spontaneous exploratory motor behavior of
4 month old mice. They observed a significant slowdown of the hippocampal theta
rhythm, which is known to play a crucial role in learning and memory function.
Furthermore, they found decreased levels of gamma long-range synchronization in
the KO animals, while power and peak frequency in the gamma band oscillations
(30–80 Hz) recorded from neocortex and hippocampus remained unchanged. As a
result, it was hypothesized that the lack of physiologically phosphorylated Tau
during early stages of development may influence the maturation of parvalbumin-
containing interneurons affecting the spatiotemporal structure of long-range
gamma synchronization between hippocampus and neocortex.
It was recently demonstrated that Tau exerts an important mediatory role in
regulating the interaction between protein kinase C binding protein 1 and GluA2, a
molecular mechanism fundamental to AMPA receptor internalization [73]. Bio-
chemical and electrophysiological assays have allowed to show that specific phos-
phorylation at S396 of Tau is related to and required for LTD. In addition, the
absence of Tau led to the reversion of deficiencies in spatial memory, pointing out a
relevant role of Tau in hippocampal LTD. Thus, Tau seems to be decisively involved
in the maintenance of physiological synaptic transmission and synaptic plasticity.
For many years, in terms of location, Tau has been considered to be an exclu-
sively intracellular protein. However, Tau can be released from neurons and it has
been found in the cerebrospinal fluid of AD patients. This feature may affect
network functions by directly influencing the activity of multiple neurons. Stimu-
lation of neuronal activity can induce Tau release from healthy cortical neurons,
suggesting that Tau secretion is a physiological process [74]. In vivo microdialysis
has proven that increasing neuronal activity raises the level of extracellular Tau. The
elimination rate of Tau from the extracellular space in the brain is slow suggesting
that Tau can be present for long times outside of neurons and influence other cells.
Extracellular Tau has a reduced phosphorylation state and is enriched in C-
terminally truncated forms. Besides, it has been demonstrated that a Tau fragment
resulting from the cleavage through the effector caspase-3 exhibits enhanced secre-
tion [75]. It is not yet clear in which form Tau is present in the extracellular space
and how it potentially influences other neurons. Extracellular Tau might affect
network functions by acting on other cells through receptor-mediated mechanisms.
Alternatively, extracellular Tau might be taken up by other neurons and modulate
their signaling cascades. Several studies have reported uptake of Tau aggregates and
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oligomers, which may cause network damage by propagation of protein abnormal-
ities. For instance, it has been suggested a prion-like spreading of a pathogenic
misfolded Tau in a deterministic manner to distinct brain regions [76]. However, it
is not clear whether or not extracellular soluble Tau is internalized by neurons at
physiological conditions. Application of exogenous Tau from cerebral cortex of AD
brain evoked a strong LTP inhibition at CA3-CA1 synapses in hippocampal brain
slices being elicited by theta burst stimulation. Moreover, a short exposure to
oligomers, but not monomers, of extracellular recombinant human Tau causes a
concentration-dependent impairment of LTP in the CA3-CA1 pathway and mem-
ory formation [77]. These effects were reproduced both by Tau oligomers from AD
human specimens, as well as those produced in mice overexpressing the human
Tau. In vitro conditions has evidenced that oligomerized Tau passes the cell mem-
brane and is internalized by neurons. However, it is unclear whether extracellular
Tau acts in these experiments through receptor-mediated mechanisms or after
internalization.
With all of it, it appears clear that Tau exerts systemic effects and modulates
network functions both in the CNS and the peripheral nervous system. Conse-
quently, changes in the Tau level will produce various side effects. Though most
available data are still controversial at length, general trends begin to become
apparent from several experimental approaches. The course of motor impairments
as a consequence of reduced Tau levels at advanced age might be caused by an
impact on the peripheral motor system. Mild cognitive and memory deficits and a
disruption of physiological synaptic transmission and synaptic plasticity have been
repeatedly reported. Even posttranslational modifications of Tau possessing patho-
logic effect may serve protective functions for synapses, which would be impaired
in circumstances of Tau depletion. Experiments with hibernating animals have
rendered evidence for a protective function of Tau phosphorylation, providing a
striking model for extreme plasticity, as numerous synaptic contacts are lost during
hibernation and regenerated in a brief period of time after animal awakening. In
these animals, a physiologically adaptive process associated with synaptic plasticity
seems to be supported by a reversible hyperphosphorylation of soluble Tau [78].
Furthermore, a small amount of Tau has been localized and accumulated in the
nuclear compartment, in both the soluble and chromatin-bound fractions. A puta-
tive role of Tau in both nucleolar organization and DNA damage protection and
chromosome stability have been proposed, since wild-type Tau prevents DNA
damage under oxidative stress or hyperthermic conditions. Recently, it has been
observed that promoting Tau nuclear translocation and accumulation, by Tau
overexpression or disengagement from MTs, enhances the expression of the vesic-
ular glutamate transporter VGluT1 [79], a disease-fundamental gene directly
involved in glutamatergic transmission. Significantly, the P301L mutation in Tau
gene, linked to frontotemporal dementia FTDP-17 [80], disturbs this mechanism
leading to a function loss. This fact demonstrates a direct physiological role of Tau
on modulating gene expression, particularly the expression of the vesicular gluta-
mate transporter VGluT1, which is known to be strongly upregulated in early
phases of tauopathies. Thus, alterations of this mechanism may be at the basis of the
onset of neurodegeneration.
Taken together, though most current approaches to target Tau are based on its
actions on MTs and are aimed at counteracting the aggregation of its soluble pool,
unlinked functions of Tau to its MT-binding properties have been suggested lately.
Therefore, in view of the evidence supporting considerable modulatory and poten-
tially protective functions of Tau at physiological conditions, the strategies aimed at
modulating the amount and modification of Tau should be carefully taken into
consideration when planning Tau-based therapies.
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7. The signaling pathway of the Wnt protein family
In humans, Wnts are a family of secreted glycolipoproteins (19 members) that
are evolutionarily conserved [81]. Wnts are essential for axon pathfinding, den-
dritic development, and the formation and function of synapses [82]. The contri-
bution of Wnts to synapse development in different model systems has been
supported widely [83].
Several Wnt proteins (Wnt7a, Wnt5a, and Wnt3a) that signal through different
receptors promote pre-synaptic differentiation [84]. Besides, Wnts signaling
promotes excitatory synapse formation and spine growth [85]. Unlike Wnt7a,
Wnt5a promotes inhibitory post-synaptic assembly by increasing GABAA receptor
clustering and enhancing the amplitude of inhibitory postsynaptic currents [86].
Members of the Wnt family might regulate excitatory and inhibitory post-synaptic
properties, differentially. Moreover, Wnts act bidirectionally to promote the
assembly of both sides of the synapse [84].
Regulation of synaptic transmission by Wnt proteins has been demonstrated by
electrophysiological recordings. Members of the Wnt family can modulate neuro-
transmission pre-synaptically and post-synaptically [84]. For instance, gain of
function of Wnt7a has shown to promote transmitter release in cultured neurons.
Post-synaptically, Wnt7a enhances synaptic strength by increasing the number of
AMPA receptors at the post-synaptic membrane in hippocampal neurons and
Wnt5a potentiates post-synaptic NMDAR-mediated currents through RoR2 recep-
tors in hippocampal neurons.
Members of the Wnt family are regulated by neuronal activity. Thus, neuronal
activity modulates the mRNA and protein levels of Wnts and their receptors in
different model systems. Wnt blockade completely abolishes activity-mediated
synapse formation in cultured neurons [87]. Blockade of endogenous Wnt proteins,
with secreted frizzled-related proteins (Sfrps), severely impairs LTP [88].
Conversely, addition of Wnt proteins can facilitate LTP [89].
Research is been currently focused on identifying the mechanisms by which
Wnts modulate LTP. In this regard, Wnt5a has been shown to regulate NMDAR-
mediated synaptic transmission in acute hippocampal slices [89]. However, it does
not affect endogenous synaptic AMPAR localization or dendritic spine size in hip-
pocampal cultured neurons [88]. Then, it is suggested that Wnt5a may contribute to
later stages of LTP.
Endogenous Wnt signaling is required for structural and functional plasticity
during LTP as it has been demonstrated. A study shows that Wnt7a/b regulate the
early stages of NMDAR-dependent LTP [88]. Acute blockade of endogenous Wnts
with Sfrps attenuates LTP induced by stimulating acute hippocampal slices at high
frequency or LTP induced by glycine application in hippocampal neurons. Changes
in dendritic spine structure, augmented synaptic strength, and synaptic localization
of AMPA receptors are inhibited in the presence of Sfrps during LTP. Intriguingly,
gain of function via single-particle tracking and super-ecliptic pHluorin-tagged
AMPA receptors in hippocampal neurons has proven that Wnt7a quickly enhances
dendritic spine growth, recruitment of synaptic AMPA receptors, and synaptic
strength, similar to the early phases of LTP [88].
A proper balance between canonical and non-canonical Wnt signaling might
determine whether synapses are lost or only their function is affected [84]. A mouse
model characterized by a Wnt deficiency in the adult brain has demonstrated that
Wnt proteins constitute a requirement for synapse stability and synaptic plasticity
[90]. Transgenic mice expressing the Wnt antagonist Dickkopf-1 (Dkk1) protein in
hippocampus display a loss of excitatory synapses, altered LTP, enhanced LTD, and
deficits in long-term memory [91]. Acute blockade of endogenous Wnts by Sfrps
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does not affect the number of excitatory synapses but inhibits LTP induction. This
is not due to acute versus long-term exposure to Wnt antagonists, as Dkk1 also
rapidly induces synapse loss in mature neurons [92]. Both antagonists have a dif-
ferent mechanism of action. While Sfrps inhibits Wnt function by means of binding
to Wnt proteins, Dkk1 affects a canonical Wnt signaling pathway by blocking the
low density lipoprotein receptor-related protein 6 (LRP6), an essential Wnt
co-receptor.
Growing evidence suggests that deficient Wnt signaling affects synaptic integ-
rity in the adult brain. In AD, particularly, decreased levels of Wnt signaling could
weaken synaptic function resulting in the subsequent degeneration and loss of
synapses characteristic of this condition. Expression of the endogenous Wnt antag-
onist Dkk1 is increased in the brain of AD patients. On other hand, Aß quickly
induces Dkk1 expression and blockade of Dkk1 protects synapses from Aß [92].
Besides, a variant of LRP6 has been linked to late onset AD [93] and deletion of
LRP6 magnifies pathology in an AD mouse model [94]. These findings along with
those obtained from mice expressing Dkk1 [91] demonstrate that deficits in Wnt
signaling affect synaptic integrity in the adult brain. In AD, diminished levels of
Wnt signaling could mine synaptic function leading to the subsequent degeneration
and synapse loss which is characteristic of this condition. Reactivation of Wnt
signaling might restore connectivity after substantial synapse degeneration. In fact,
the ceasing of Dkk1 expression in transgenic mice that express Dkk1 fully restores
the structural and functional plasticity and hippocampal-dependent memory [91].
Together, these studies prove the regenerative capacity of neurons in the adult
hippocampus to assemble synapses within functional circuits after degeneration.
8. Extracellular vesicles in the intercellular communication
In the CNS, extracellular vesicles (EVs) have emerged as key players in the
intercellular communication that underlies physiological processes such as synaptic
plasticity, maintenance of myelination, and neuronal and glial response to brain
injury. EVs are secreted membrane-enclosed ‘packages’ that contain cytosolic pro-
teins, membrane proteins, mRNAs, noncoding RNAs, and even DNA [95].
In order to modulate synaptic plasticity, neuronal EVs can transfer cargo to
other neurons. It has been suggested an uptake of neuronal EVs by microglia to
enhance microglial pruning of synapses. Moreover, increased astrocytic uptake of
glutamate may result from internalization of neuronal EVs into astrocytes. In turn,
EVs from astrocytes have been shown to contain cargo-mediating neuroprotection
under neuronal stress. Oligodendrocyte-derived EVs increase neuronal firing medi-
ate as well as neuronal stress resilience [96]. Moreover, oligodendrocyte-derived
EVs may behave as auto-inhibitors in expansion of myelin. As for microglial EVs,
they may modulate neuronal firing, and also propagate inflammation and destabi-
lize synapses in a CNS injury setting. In terms of neurodegenerative diseases, EVs
are involved in both the spreading and clearance of neurotoxic protein aggregates
[97]. EVs have also been shown to cross the blood-brain barrier particularly under
inflammatory conditions, enabling molecular crosstalk between brain cells and the
periphery [98].
The coupling of neuronal EV release to synaptic activity could be functionally
relevant for plasticity-associated processes. For instance, activity-dependent dis-
posal or transfer of AMPA receptor components, which have been shown to flow
throughout EVs, may constitute a mechanism for the adjustment of synaptic
strength [99]. Moreover, it has been suggested that neuronal EVs act as trans-
synaptic carriers of signaling proteins involved in synaptic plasticity. In a series of
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in vivo studies at the Drosophila neuromuscular junction, it has been shown that the
Wnt-family signaling protein Wingless was protected driving toward EVs by the
trafficking protein Evi/Wntless for trans-synaptic transport and hampering this
trafficking impaired synaptic bouton formation [100]. In the same model system,
synaptotagmin 4 has been found to drive on EVs from the presynaptic motor
neuron to the postsynaptic muscle, and this directional transport was fundamental
for activity-dependent growth of presynaptic structures.
Plasticity-associated local protein synthesis at synapses appears to be affected by
the activity-dependent trafficking of specific RNAs into EVs. In one study, depo-
larization of differentiated neuroblasts has been found to be correlated with a
depletion of specific miRNAs from neurites, associated with an enhancement of a
specific subset of these miRNAs in EVs. Furthermore, neuronal EVs have been
recently shown to package mRNA in association with the activity-regulated
cytoskeleton-associated protein (Arc), described as a master regulator of synaptic
plasticity [101]. Arc appeared to self-assemble into capsids as if it were a viral
group-specific antigen (Gag) protein, encapsulating its own mRNA or other highly
abundant mRNAs, and trafficking between cells by means of EVs. The blockage of
Arc trafficking from presynaptic terminals to the postsynaptic muscle, at the Dro-
sophila neuromuscular junction, caused aberrations in synapse maturation and
activity-dependent plasticity [102]. Therefore, Arc capsid-containing EVs may
constitute a retrovirus-like mechanism for trans-synaptic transfer of at least Arc
mRNA during processes associated with synaptic plasticity. The biological origin
and composition of Arc-containing EVs, as well as the scope of the EV-associated
Arc transport in the mammalian brain, have yet to be studied in the future.
It is intriguing that neuronal EVs can also transfer cargo to other cells in the
brain, modulating their behavior with a potential impact on synaptic activity. One
study found that the uptake of neuronal miR-124a-carrying EVs into astrocytes was
correlated with overexpression of excitatory amino acid transporter 2/glutamate
transporter-1 (EAAT2/GLT1), which could modulate synaptic activity via an
increased uptake of glutamate into perisynaptic astrocytes [103]. Moreover, EVs
from differentiated PC12 cells seemed to promote microglial phagocytosis of
degenerating neurites by means of increasing the microglial expression of comple-
ment component 3 (C3), a factor associated with synaptic pruning. The release of
EVs from active neurons could thereby serve to the removal of less functional
synapses during developmental or learning-associated remodeling of neuronal
connections, although validation of this finding is warranted in at least primary
neurons.
With regard to glial EVs, they have been described to provide neurons with
support and feedback on synaptic activity. And so, for example, oligodendrocytes
contain multivesicular endosomes at sites near the axonal surface, and secrete EVs
particularly in response to glutamate. While microglia appeared to degrade
oligodendrocyte-derived EVs, neuronal internalization of these EVs led to func-
tional cargo retrieval along with an increase in neuronal firing rate and modified
gene expression of several plasticity-related targets, such as VGF nerve growth
factor inducible and BDNF [104]. Microglial microvesicles (MVs), for its part,
released in response to ATP and increased excitatory neurotransmission through
stimulation of neuronal sphingolipid metabolism and a consequent increase in the
presynaptic release of neurotransmitters. The functionality of the MVs seemed to
depend on a lipid or a surface component since sheared MVs retained the function-
ality [105]. In another study, microglial EVs have shown to carry the active
endocannabinoid N-arachidonoylethanolamine on their surface, which bound to
presynaptic type 1 cannabinoid receptors, and thereby decreased the release of the
neurotransmitter GABA. Overall, glial EVs seem to influence both excitatory and
15
Homeostatic Plasticity and Therapeutic Approaches in Neurodegeneration
DOI: http://dx.doi.org/10.5772/intechopen.86415
inhibitory neurotransmission, providing regulatory feedback particularly on pre-
synaptic activity [95].
As remarkable, EVs have emerged as possible therapeutic agents in
inflammation-mediated demyelinating diseases, such as multiple sclerosis (MS).
Increasing evidence suggests that EVs display anti-inflammatory properties,
reducing the number of activated inflammatory microglial cells, supporting oligo-
dendrocytes and protecting neurons. A very recent study illustrates a putative
therapeutically role for EVs. Intravenously administered EVs derived from mesen-
chymal stem cells (MSCs) from human adipose tissue might mediate recovery in
Theiler’s murine encephalomyelitis virus (TMEV)-induced demyelinating disease, a
progressive model of MS [106]. Intravenous EV administration in SJL/J mice
improved motor deficits, lowered brain atrophy, enhanced cell proliferation in the
subventricular zone, and decreased inflammatory infiltrates in the spinal cord of
animals infected with TMEV. In addition, EV treatment was capable of modulating
neuroinflammation, given glial fibrillary acidic protein and Iba-1 staining were
reduced in the brain, whereas the expression of myelin was increased. Modifica-
tions of morphology in microglial cells from the spinal cord may indicate that EVs
also modulate the activation state of microglia. EV administration attenuates motor
deficits through immunomodulatory actions, diminishing brain atrophy and pro-
moting remyelination.
So far, there is no evidence regarding the therapeutic potential of EVs during the
neurodegenerative phase of MS. Further studies are necessary to establish EV
delivery as a possible therapy for the neurodegenerative phase of MS.
9. Estrogen involvement in non-reproductive functions
Estrogens from neural origin are involved in a variety of non-reproductive
functions including regulation of neurogenesis, neuronal development, synaptic
transmission, and plasticity in brain regions not directly related with the control of
reproduction [107]. Estrogens regulate the expression of genes for various specific
subtypes of dopamine (DA) receptors and 5-HT receptors in a region-specific
manner to contribute to behavioral responses to changes of the internal and external
environment.
DA neurotransmission of the ventral tegmental area (VTA)-nucleus accumbens
(NAc) pathway associated with motivation is modulated by estrogens, which
results in functional differences of the mesolimbic dopaminergic pathway and
explains numerous sex differences in reward processing and related behavior
described in human and animal studies [108]. Generally, increased circulating levels
of estrogens in rodents, either during their estrous cycles or by estrogen treatment,
have shown to contribute to elevated dopaminergic signaling. Estrogens influence
manifold aspects of dopaminergic neurotransmission both presynaptically and
postsynaptically, including: (a) DA synthesis, release, and degradation; (b) presyn-
aptic and postsynaptic receptors; and (c) DA transporters that uptake DA from the
synapse to terminate DA neurotransmission. Nuclear and membrane-associated
estrogen receptors (ERs) may constitute the mechanisms by which estrogens affect
the dopaminergic system. Precisely, ERs are distributed in dopaminergic pathways
involved in reward, what is pertinent to the effects of estrogens on the CNS reward
system [109]. In male mice, dopaminergic projections from the VTA to the ventral
caudate express the ERβ isoform, while dopaminergic projections to the dorsal
caudate do not. Dopaminergic projections to the basolateral amygdala also express
ERβ. Estrogens also act rapidly through membrane-associated ERs on dopaminergic
neurons in the striatum to affect DA release. Estrogens increase the activity of the
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tyrosine hydroxylase (TH) and thus DA synthesis in the NAc by means of both
nuclear ERs and membrane ER; induce presynaptic DA release in the striatum; and
decrease DA turnover in the NAc and reduce degradation of DA so that DA remains
longer at the synapse [108].
Estrogens upregulate the expression and activity of tryptophan hydroxylase
(TPH) to increase 5-HT biosynthesis. Estrogen administration has been found to
increase the TPH mRNA level [110]. In ovariectomized (OVX) guinea pigs, estro-
gen treatment alone increases the protein expression of TPH at the dorsal raphe
nucleus (DRN). Surprisingly, while treatment with estrogen alone increases levels
of TPH mRNA and TPH protein, it does not modify 5-HT content; rather, the
treatment combining estrogen plus progesterone enhances 5-HT levels at both the
DRN and the projected medial basal hypothalamus in guinea pigs [111]. Thus, there
is a disparity in the sex hormone regulation of TPH mRNA and TPH protein levels
versus 5-HT production in estrogen-treated animals, likely due to activity of TPH
that is regulated by means of phosphorylation by protein kinase A (PKA) [112].
Since only phosphorylated TPH possesses catalytic activity, progesterone treatment
might increase PKA expression and activity of TPH. After loss of ovarian function
in many women, there may be an adjustment in the serotonergic neurons so that
TPH protein levels recover. This also may indicate that the decline in TPH expres-
sion is a potential point of vulnerability in pre- and postmenopausal women who
experience mental disorders such as depression related to the decreased level of
5-HT.
Estrogens regulate the 5-HT receptors, 5-HT2A and 2C, which display classic
features of G protein-coupled receptors. The 5-HT2A receptor has been associated
with suicide and depression, and its mRNAs are found in brain areas fundamental
for the mood control, mental state, and cognition [113]. In humans, 5-HT2A recep-
tor mRNA is found in the cortex and hippocampus, but not in the DRN, striatum,
substantia nigra, or cerebellum [114]. Estrogens increase 5-HT2A receptor mRNA
and binding site densities in the male rat brain. Healthy men have shown signifi-
cantly higher levels of 5-HT2A receptor binding capacity than healthy women in the
frontal and cingulate cortices, according to determinations by PET and radiotracer
18F-labeled altanserin [115]. Human studies suggest that estrogens increase 5-HT2A
binding in higher forebrain regions.
The NAc receives major inputs from the amygdala and projects to the cortex and
hypothalamus. These regions are fundamental for the cognitive function, emotion,
mental state, mood, and neuroendocrine control. Thus, increase in 5-HT2A receptor
densities by estrogen stimulation in these stated regions would control behavior and
mood. A single administration of estradiol to OVX rats induces a significant increase
in 5-HT2A receptor labeling in the NAc, the amygdala, DRN, anterior frontal,
anterior cingulate, and primary olfactory cortex [116]. Moreover, concomitantly
with the spontaneous estrogen-induced LH surge, 5-HT2A receptor densities
increase compared to diestrous females or males in the frontal and cingulate cortex,
olfactory tubercle and NAc. OVX produces a reduction of 5-HT2A receptor mRNA
and protein levels, and long-term estrogen replacement reverses this effect in the
frontal cortex [117]. The receptor 5-HT2C, a relevant contributor of many psychi-
atric and neurological disorders, is the most prominent 5-HT receptor subtype in
the rat brain. 5-HT2C mRNA and protein are found in discrete regions of the rat
brain. In the primate hypothalamus, dense populations of 5-HT2C mRNA-labeled
cells are found in the anterior hypothalamus, periventricular nuclei, ventromedial
nucleus, dorsal hypothalamic area, lateral hypothalamus, arcuate nucleus, and
infundibular nucleus [118].
Estrogens regulate 5-HT auto-inhibition via the 5-HT1A auto-receptor. The
5-HT1A auto-receptor suppresses 5-HT synthesis by inhibiting firing of
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serotonergic neurons at the DRN and median raphe and inhibiting 5-HT release in
the hippocampus [119]. Therefore, the blockage of 5-HT1A receptors results in an
antidepressant-like activity. Estrogen treatment lowers the 5-HT1A mRNA level
in the dentate gyrus, CA2 region of the hippocampus, and DRN of OVX rats and in
the DRN and median raphe of castrated rhesus monkeys, according to measurement
by in situ hybridization. The5-HT1A auto-receptor is linked to an inhibitory
G protein of the Gi/o/zfamily [120].
Estrogen treatment reduces 5-HT uptake to presynaptic cells by means of
decreasing gene expression, translation, protein phosphorylation, trafficking, and
stability of the serotonin transporter (SERT) [121]. Estrogens reduce SERT mRNA
signal in the DRN of castrated rhesus monkeys treated with estrogen compared to
the castrated control group and decrease [3H]-paroxetine binding, a selective indi-
cator of 5-HT reuptake sites, in the hippocampus of estrogen-treated rats. Acute
estrogen administration decreases SERT mRNA levels and 5-HT1A mRNA levels
and binding. Thus, estrogen replacement therapy in postmenopausal women might
decrease expression of the SERT gene and SERT protein [107]; thus 5-HT may
remain longer in the extracellular space to continue neurotransmission. However,
such argument does not support the observations that humans with depression have
lower levels of 5-HT reuptake sites than healthy humans [122]. It might be that
there is a mitigated 5-HT release and reduced levels of 5-HT in humans with
depression to begin with, and a less 5-HT reuptake [107].
As we described, estrogens enhance 5-HT signaling via increasing 5-HT biosyn-
thesis, upregulating expression and binding of receptors 5-HT2A and 5-HT2c,
downregulating activity and expression of the 5-HT1A auto-receptor, decreasing
expression of SERT gene and SERT protein allowing 5-HT to remain in the extra-
cellular space for a longer period of time to continue neurotransmission, and
decreasing 5-HT metabolism [107]. Consequently, the hypothesis of estrogen pro-
tection [123] claims that adjunctive estrogen treatment is beneficial at improving
both symptoms of schizophrenia and the cognitive function, most notably in
women. So far, the majority of studies on hormone replacement therapy for mood
disorders have shown a positive response. Thus, estrogen has been demonstrated to
improve mood in multiple mental illnesses, including major depressive disorder.
Most recently, adjunctive estradiol treatment has been suggested as a promising
treatment for women with comorbid depression and schizophrenia. In this direc-
tion, exploration of the impact of estrogen on serotonergic and other neurochemical
pathways plus brain circuitry may guide not only the development of new hormone
treatments but also assist in understanding the etiology of premenstrual dysphoric
disorder, postnatal and perimenopausal depression, and even schizophrenia in
women.
On the other hand, estrogens have shown that they do not always improve
learning and memory. As an experimental example, acute administration of high
doses of 17β-estradiol and progesterone can impair performance in the memory test
of Morris water maze. And most importantly, there is coherence among human
studies since high endogenous levels of 17β-estradiol are associated with poor per-
formance on spatial tasks and cognitive function (Montreal Cognitive Assessment
scale) and high dose of exogenous 17β-estradiol impairs recognition memory. It is
fundamental to assume that estradiol exerts a curvilinear influence on
hippocampal-dependent performance, with low and high levels impairing versus a
medium dose improving performance on a variety of tasks [124]. Similar dose
response has been observed in the rapid effects of estrogens on dendritic spines,
therefore, studies on the effects of estrogens on cellular morphology should take
dose response into account. Furthermore, long-term exposure to estrogens can
similarly result in dose-dependent responses on learning and memory, with low
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levels of 17β-estradiol reinforcing spatial working memory and high levels of estra-
diol hampering spatial working and reference memory. Studies have also shown
that, whereas there is a dose-dependent facilitation in contextual fear conditioning
by 17β- and 17α-estradiol, estrone results in dose-dependent impairments in con-
textual fear conditioning. Thus, it is essential to consider that the dose, frequency of
administrations, and type of estrogen(s) utilized along with the type of memory
task performed and the time point estrogens are administered (during acquisition
or retrieval), are critical to the learning outcomes [124].
10. Conclusion
This review has concentrated on some cellular processes and signaling pathways
acting during homeostatic molecular remodeling and their potential involvement in
the maladaptive plasticity occurring in multiple neuropathologic conditions such as
neurodegeneration and neuropsychiatric disorders.
There seem to be independent mechanisms for regulating presynaptic and post-
synaptic strength, and there is evidence for independent homeostatic mechanisms
operating on global and local spatial scales.
Involvement of different pharmacological approaches to compensate neuro-
transmission imbalance are under study, which may be considered as potential
therapeutic approaches in neuropathologic conditions.
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